NCT07336966Not yet recruiting
Does Recessive Optic Atrophy Due to WFS1 Exist?
Does Recessive Optic Atrophy Due to WFS1 is a Specific Entity Different From Wolfram Syndrome?
Source: ClinicalTrials.gov · Last updated 13 Jan 2026
Brief summary (registry, in English)
All patients with Wolfram syndrome and recessive optic atrophy due to a mutation of the WFS1 from a single Center were included in a retrospective study. Evolution of the visual acuity since the occurrence of the optic atrophy and its last value, OCT data, genetic data and systemic manifestations were analyzed.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 45 (estimated)
- First submitted
- 15 Nov 2025
- Start date
- Feb 2026
- Primary completion date
- Mar 2026
- Lead sponsor
- Hôpital Necker-Enfants Malades
- NCT number
- NCT07336966
What you commit to
- Study type: Observational
- Planned participants: 45
- From Feb 2026 to the primary completion date, Mar 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- WFS2 mutation
Who the study is looking for
- WFS1 mutation
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.